

ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/  
Form SC 13G  
December 06, 2006

|  |
|--|
| OMB<br>APPROVAL  |
| OMB<br>Number:<br>3235-0145                                  |
| Expires:<br>February 28,<br>2009                             |
| Estimated<br>average<br>burden<br>Hours per<br>response 10.4 |

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
Under the Securities Exchange Act of 1934  
(Amendment No. \_\_)\*

Arrhythmia Research Technology, Inc.

-----  
(Name of Issuer)

Common Stock

-----  
(Title of Class of Securities)

042698308

-----  
(CUSIP Number)

November 27, 2006  
-----

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1745 (3-06)

Page 1 of 6 pages

-----  
CUSIP No. 042698308  
-----

- 
1. Names of Reporting Persons  
I.R.S. Identification Nos. of above persons (entities only)

Healthinvest Partners AB

- 
2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

- 
3. SEC Use Only

- 
4. Citizenship or Place of Organization

Sweden

-----

Number of 5. Sole Voting Power 145,300

Shares -----

Beneficially 6. Shared Voting Power 0

Owned by -----

Each 7. Sole Dispositive Power 145,300

Reporting -----

Person With: 8. Shared Dispositive Power 0

- 
9. Aggregate Amount Beneficially Owned by Each Reporting Person

145,300

---

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

---

11. Percent of Class Represented by Amount in Row (9)

5.4%

---

12. Type of Reporting Person (See Instructions)

IA, HC

---

-----  
CUSIP No. 042698308  
-----

-----  
1. Names of Reporting Persons  
I.R.S. Identification Nos. of above persons (entities only)

HealthInvest Global Long/Short Fund

-----  
2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

-----  
3. SEC Use Only

-----  
4. Citizenship or Place of Organization

Sweden

-----  
Number of 5. Sole Voting Power 145,300

Shares -----

Beneficially 6. Shared Voting Power 0

owned by -----

Each 7. Sole Dispositive Power 145,300

Reporting -----

Person With: 8. Shared Dispositive Power 0

-----  
9. Aggregate Amount Beneficially Owned by Each Reporting Person

145,300  
-----

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

-----  
11. Percent of Class Represented by Amount in Row (9)

5.4%

-----  
12. Type of Reporting Person (See Instructions)

OO  
-----

Page 3 of 6 pages

Item 1(a). Name of Issuer:

Arrhythmia Research Technology, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

25 Sawyer Passway  
Fitchburg, Massachusetts 01420

Item 2(a). Name of Persons Filing:

Healthinvest Partners AB and HealthInvest Global Long/Short Fund

Healthinvest Partners AB is the investment advisor and control person of HealthInvest  
Global

Long/Short Fund, a security holder of the Issuer. HealthInvest Global Long/Short Fund  
is a  
specialty fund organized pursuant to the Swedish Mutual Funds Act.

Item 2(b). Address of Principal Business Office or, if none, Residence:

Arsenalsgatan 4  
SE-111 47 Stockholm  
Sweden

Item 2(c). Citizenship:

See the response(s) to Item 4 on the attached cover page(s).

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

042698308

Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether  
the person

filing is a:

Not Applicable

Item 4. Ownership

(a). Amount beneficially owned:

See the response(s) to Item 9 on the attached cover page(s).

(b). Percent of Class:

See the response(s) to Item 11 on the attached cover page(s).

(c). Number of shares as to which the person has:

(i). Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).

(ii). Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).

(iii). Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).

(iv). Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).

Item 5. Ownership of five percent or less of a class.

Not Applicable

Item 6. Ownership of more than five percent on behalf of another person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary which acquired the Security being reported on

by the Parent Holding Company.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to

above were not acquired and are not held for the purpose of or with the effect of changing or

influencing the control of the issuer of the securities and were not acquired and are not held in

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form SC 13G  
connection with or as a participant in any transaction having that purpose or effect.

Page 5 of 6 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 6, 2006

HEALTHINVEST PARTNERS AB

By: /s/ ANDERS HALLBERG

-----  
Name: Anders Hallberg  
Title: Managing Director and CEO

HEALTHINVEST GLOBAL LONG/SHORT FUND

By: /s/ ANDERS HALLBERG

-----  
Name: Anders Hallberg  
Title: CEO of Managing Company

